- Home
- BNR vs ABP Comparison
BNR vs ABP Comparison
Compare BNR & ABP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNR
- ABP
- Stock Information
- Founded
- BNR 2014
- ABP N/A
- Country
- BNR China
- ABP United States
- Employees
- BNR N/A
- ABP N/A
- Industry
- BNR Medical Specialities
- ABP Biotechnology: Pharmaceutical Preparations
- Sector
- BNR Health Care
- ABP Health Care
- Exchange
- BNR Nasdaq
- ABP Nasdaq
- Market Cap
- BNR 28.6M
- ABP 29.8M
- IPO Year
- BNR 2020
- ABP 2022
- Fundamental
- Price
- BNR $5.38
- ABP $3.18
- Analyst Decision
- BNR
- ABP
- Analyst Count
- BNR 0
- ABP 0
- Target Price
- BNR N/A
- ABP N/A
- AVG Volume (30 Days)
- BNR 20.0K
- ABP N/A
- Earning Date
- BNR 11-29-2024
- ABP N/A
- Dividend Yield
- BNR N/A
- ABP N/A
- EPS Growth
- BNR N/A
- ABP N/A
- EPS
- BNR N/A
- ABP N/A
- Revenue
- BNR $70,154,674.00
- ABP N/A
- Revenue This Year
- BNR $52.90
- ABP N/A
- Revenue Next Year
- BNR $48.35
- ABP N/A
- P/E Ratio
- BNR N/A
- ABP N/A
- Revenue Growth
- BNR N/A
- ABP N/A
- 52 Week Low
- BNR $2.62
- ABP N/A
- 52 Week High
- BNR $9.99
- ABP N/A
- Technical
- Relative Strength Index (RSI)
- BNR 80.41
- ABP N/A
- Support Level
- BNR $4.55
- ABP N/A
- Resistance Level
- BNR $3.89
- ABP N/A
- Average True Range (ATR)
- BNR 0.42
- ABP 0.00
- MACD
- BNR 0.23
- ABP 0.00
- Stochastic Oscillator
- BNR 99.26
- ABP 0.00
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through our in-hospital model and smaller hospitals through our central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.